Literature DB >> 11913728

Polymorphisms in the ABC drug transporter gene MDR1.

U Brinkmann1, M Eichelbaum.   

Abstract

In addition to genetically variable metabolic enzymes such as Cyp p450 proteins, blood and tissue levels of many drugs are influenced by controlled transport across compartmental boundaries. Major determinants in these transport processes are ATP-dependent efflux pumps such as P-glycoprotein and related proteins (eg MRPs), which can influence the bioavailability and CNS concentrations, as well as disposition of drugs. In addition to its recognized role in the development of multiple chemotherapy resistances, experimental evidence for the relevant influence of the MDR1 gene encoded P-glycoprotein, on the pharmacology of many other drugs has been gathered by the analyses of knockout mice, as well as in clinical studies. Recently, functional genetic polymorphisms in the MDR1 gene have been identified which influence the distribution and bioavailability of PGP substrates.

Entities:  

Mesh:

Year:  2001        PMID: 11913728     DOI: 10.1038/sj.tpj.6500001

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  26 in total

Review 1.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Prioritization of SNPs for genome-wide association studies using an interaction model of genetic variation, gene expression, and trait variation.

Authors:  Hyojung Paik; Junho Kim; Sunjae Lee; Hyoung-Sam Heo; Cheol-Goo Hur; Doheon Lee
Journal:  Mol Cells       Date:  2012-03-28       Impact factor: 5.034

3.  No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients.

Authors:  Darinka Todorova Petrova; Petya Nedeva; Svilen Maslyankov; Svetoslav Toshev; Nikolay Yaramov; Srebrena Atanasova; Draga Toncheva; Michael Oellerich; Nicolas von Ahsen
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-03       Impact factor: 4.553

Review 4.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  On the relationship between drug's size, cell membrane mechanical properties and high levels of multi drug resistance: a comparison to published data.

Authors:  Cyril Rauch
Journal:  Eur Biophys J       Date:  2008-12-10       Impact factor: 1.733

6.  Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.

Authors:  Catherine Bourguinat; Joseph Kamgno; Michel Boussinesq; Charles D Mackenzie; Roger K Prichard; Timothy G Geary
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

7.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

Review 8.  Toward a mechanical control of drug delivery. On the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data.

Authors:  Cyril Rauch
Journal:  Eur Biophys J       Date:  2009-03-19       Impact factor: 1.733

9.  Role of multidrug transporters in neurotherapeutics.

Authors:  Manna Jose; Sanjeev V Thomas
Journal:  Ann Indian Acad Neurol       Date:  2009-04       Impact factor: 1.383

10.  Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.

Authors:  Christian Friedrich; Stephan Glund; Dominick Lionetti; C James Kissling; Julian Righetti; Sanjay Patel; Ulrike Graefe-Mody; Silke Retlich; Hans-Juergen Woerle
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.